UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $26
Immuneering Rises on Orphan Drug Designation for Treatment of Pancreatic Cancer
The significant risks in November are undergoing crucial changes.
Less than a month away from the usa presidential election day on November 5th, the market is starting to price in the risks of the election results. Currently, Trump has regained a leading advantage, adding variables to the election. CICC believes that for subsequent assets, the overall bullishness of the election is favorable for US stocks but tariffs are unfavorable for chinese assets; the US dollar is relatively strong, gold is neutral, interest rates are rising; bulk commodities may benefit from expectations of Trump's stimulus.
Sector Update: Health Care Stocks Higher Friday Afternoon
Sector Update: Health Care
Harris, Trump Tied in Battle for Swing States, WSJ Poll Shows -- WSJ